Posters

    Cigarette Mainstream Smoke and Gas Phase-Depleted Particulate Phase Enhance Lung Tumorigenicity in the A/J Mouse

    Stinn, W.; Büttner, A.; Arts, J. H. E.; H-Haussmann, H-J. Haussmann.

    Conference date
    Mar 6, 2005
    Conference name
    Society of Toxicology (SOT) 2005
    Link to more information
    Topic
    Summary

    Despite the established causality between tobacco smoking and lung cancer (IARC 2004), it is difficult to establish reproducible and validated animal inhalation models for this disease. These models are needed for the evaluation of potential risk-reduced products and chemoprevention. In order to further investigate the A/J mouse model for lung tumorigenicity, male A/J mice were whole-body exposed to diluted cigarette mainstream smoke from the standard reference cigarette 2R4F for 6 hours per day, 5 days per week for 5 months followed by 4 months without exposure. The animals were exposed to fresh filtered air, to whole smoke at concentrations of 0.12 or 0.24 mg total particulate matter (TPM)/l, to gas phase depleted particle phase (PP) at 0.24 mg TPM/l, which was generated by an activated charcoal adsorber, or to the gas phase of cigarette mainstream smoke at a concentration equivalent to 0.24 mg TPM/l. Lung tumor incidence and multiplicity were determined at 5 months in the control group and the whole smoke high dose group and at 9 months in all groups. At 5 months, the tumor response was comparable in the two groups. A distinct inflammation was indicated in the whole smoke high dose group by a severe increase in neutrophils and macrophages in bronchoalveolar lavage fluid. At 9 months, both cell types returned nearly to background levels; however, lung tumor incidence and multiplicity in the whole smoke groups were dose dependently higher by a factor of up to 3-fold compared to control. The lung tumor response was similar for PP and the high concentration of whole smoke. GP at the concentration used, failed to enhance lung tumor multiplicity above control level, step-serial lung section analysis confirmed the macroscopic results. The lung tumor spectrum was the same in all groups with bronchiolo-alveolar adenoma being the most prominent lung tumor type. Further research is needed to evaluate the relevance of this model with regard to the human disease.

    Related Publications

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.